Dubai Telegraph - Study shows how fast kilos return after ending weight-loss drugs

EUR -
AED 4.185954
AFN 72.947589
ALL 94.294632
AMD 417.830324
ANG 2.040717
AOA 1045.205368
ARS 1683.774482
AUD 1.652987
AWG 2.051656
AZN 1.936427
BAM 1.957791
BBD 2.287406
BDT 139.692031
BGN 1.927281
BHD 0.42823
BIF 3384.485685
BMD 1.139809
BND 1.473518
BOB 7.848117
BRL 5.900221
BSD 1.13574
BTN 107.155009
BWP 15.497553
BYN 3.232172
BYR 22340.254248
BZD 2.284202
CAD 1.61687
CDF 2587.365958
CHF 0.921797
CLF 0.026609
CLP 1047.267556
CNY 7.755088
CNH 7.754826
COP 3916.759484
CRC 516.91877
CUC 1.139809
CUP 30.204936
CVE 110.378679
CZK 24.26106
DJF 202.242967
DKK 7.474986
DOP 66.927167
DZD 151.937634
EGP 56.431257
ERN 17.097133
ETB 179.123465
FJD 2.582924
FKP 0.862513
GBP 0.862647
GEL 3.014799
GGP 0.862513
GHS 12.774212
GIP 0.862513
GMD 83.206091
GNF 9951.987623
GTQ 8.664924
GYD 237.635784
HKD 8.938364
HNL 30.389498
HRK 7.53345
HTG 148.444185
HUF 354.030908
IDR 20395.740282
ILS 3.415266
IMP 0.862513
INR 107.583366
IQD 1487.838853
IRR 1567294.214566
ISK 144.02629
JEP 0.862513
JMD 178.999641
JOD 0.808094
JPY 184.143532
KES 147.607196
KGS 99.676239
KHR 4573.750637
KMF 494.677183
KPW 1025.8284
KRW 1754.256722
KWD 0.352884
KYD 0.946479
KZT 550.449323
LAK 25242.107599
LBP 101708.364882
LKR 382.76589
LRD 206.698345
LSL 18.808453
LTL 3.36556
LVL 0.689459
LYD 7.293319
MAD 10.692259
MDL 20.159851
MGA 4841.859197
MKD 61.637914
MMK 2392.971959
MNT 4080.792105
MOP 9.171825
MRU 45.111273
MUR 54.380594
MVR 17.610087
MWK 1969.376428
MXN 19.991963
MYR 4.663073
MZN 72.832523
NAD 18.808453
NGN 1566.52989
NIO 41.79341
NOK 11.286559
NPR 171.447061
NZD 2.017627
OMR 0.438256
PAB 1.135775
PEN 3.886652
PGK 4.984002
PHP 69.821231
PKR 316.069401
PLN 4.286759
PYG 6939.995289
QAR 4.139964
RON 5.239589
RSD 117.401001
RUB 87.877339
RWF 1668.974951
SAR 4.264217
SBD 9.177687
SCR 16.007841
SDG 683.885259
SEK 11.07277
SGD 1.475243
SHP 0.850982
SLE 28.280114
SLL 23901.2267
SOS 649.051375
SRD 42.537564
STD 23591.742763
STN 24.524612
SVC 9.938279
SYP 125.985468
SZL 18.805873
THB 38.063948
TJS 10.49996
TMT 3.989331
TND 3.372273
TOP 2.744387
TRY 53.143533
TTD 7.713978
TWD 36.32035
TZS 2986.796222
UAH 51.068251
UGX 4202.346435
USD 1.139809
UYU 45.566929
UZS 13642.871264
VES 707.539771
VND 29970.704864
VUV 136.721107
WST 3.174934
XAF 656.615967
XAG 0.019708
XAU 0.000282
XCD 3.080391
XCG 2.046917
XDR 0.81662
XOF 656.615967
XPF 119.331742
YER 271.986885
ZAR 18.756463
ZMK 10259.644484
ZMW 20.499663
ZWL 367.017998
  • RYCEF

    0.7000

    18.7

    +3.74%

  • RBGPF

    0.0000

    61.3

    0%

  • NGG

    0.5900

    83.42

    +0.71%

  • GSK

    0.8000

    51.89

    +1.54%

  • VOD

    0.0500

    13.86

    +0.36%

  • BTI

    1.0900

    62.48

    +1.74%

  • CMSC

    -0.0190

    22.046

    -0.09%

  • RIO

    1.0800

    95.11

    +1.14%

  • BCC

    2.1000

    79.76

    +2.63%

  • BCE

    0.0000

    23.2

    0%

  • RELX

    -0.2300

    30.92

    -0.74%

  • CMSD

    -0.0900

    21.93

    -0.41%

  • JRI

    0.0100

    12.58

    +0.08%

  • AZN

    2.6600

    185.68

    +1.43%

  • BP

    -0.1400

    37.72

    -0.37%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: Armend NIMANI - AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

Y.Rahma--DT